Back

Radiofrequency septal ablation as a therapeutic option in refractory obstructive hypertrophic cardiomyopathy to myectomy: a case series

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Myocardial disease and valvular heart disease: miscellany Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Ms Fernanda De Brito Fortuna

Dante Pazzanese Institute of Cardiology, Sao Paulo (Brazil)

6 More presentations in this session

Presentation thumbnail
Mavacamten real-world experience: insights from the Dutch HCM Network.
Doctor P. Zwetsloot (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Impact of sodium-glucose co-transporter inhibitors in mortality and decongestion in cardiac amyloidosis: A systematic review and meta-analysis
Mrs C. Espirito Santo (Sao Paulo, BR)
Abstract Slides Video
Presentation thumbnail
Temporal and demographic disparities in cardiogenic shock mortality among patients with ischemic cardiomyopathy in the United States, 1999-2020
Doctor A. Zafar (Wigan, GB)
Abstract Slides Video
Presentation thumbnail
Cardiac mechanics in primary mitral regurgitation: effect of exercise in cardiac strain and hemodynamic parameters
Doctor I. Dimitroglou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
The prognostic value of small psoas muscle area in patients undergoing mitral edge-to-edge repair
Doctor R. Shigeno (Okayama, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial disease and valvular heart disease: miscellany

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Clinical and echocardiographic long-term follow-up after transcoronary ablation of septal hypertrophy - a retrospective register analysis
thumbnail
Congress Session
Contemporary management of hypertrophic cardiomyopathy
thumbnail
Congress Session
Septal reduction and myosin inhibitors: competing or complementary therapies?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources